US OptionsDetailed Quotes
FGEN241220P500
- 0.16
- 0.000.00%
15min DelayClose Dec 13 16:00 ET
0.00High0.00Low
0.16Open0.16Pre Close0 Volume311 Open Interest0.50Strike Price0.00Turnover0.00%IV-2.41%PremiumDec 20, 2024Expiry Date0.17Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
FibroGen Stock Discussion
Sign in to post a comment
$FibroGen (FGEN.US)$ I used to hold it during last year and my patience paid.
hope you can perform again 💪💪💪
hope you can perform again 💪💪💪
7
1
My guess is they are going to keep their doors open just long enough to sell off what little owning interest they have in the two remaining collaborative drug candidates
$FibroGen (FGEN.US)$ Officer Adib Deyaa purchased 22,123 shares of common stock on Jun 12, 2024 at an average price of $1.17 for a total value of $25,883.91.
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
$FibroGen (FGEN.US)$
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
3
No comment yet
Coach Donnie : Let’s GOOO
Jenna Ragan OP Coach Donnie : it's a risk, but I've got a feeling about these guys.
Coach Donnie Jenna Ragan OP : Calculated risk. Mitigated. Congratulations
to us in advance cheers 
